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PENGESANAN IMUNOFENOTIP ABERAN DALAM LEUKEMIA AKUT 
DAN PERKAITANNYA DENGAN PARAMETER HEMATOLOGI DAN 
KESAN RAWATAN 
ABSTRAK 
Leukemia akut merupakan salah satu kanser darah paling kerap ditemui seluruh 
dunia. Kehadiran antigen sel leukemia yang spesifik dan berbeza pada peringkat 
awal membantu untuk pendiagnosan dan mengenal pasti jenis sel yang terlibat. Sel – 
sel leukemia juga boleh menunjukkan imunofenotip aberan pada peringkat diagnosis. 
Banyak kajian telah dijalankan untuk melihat perkaitannya dengan parameter 
hematologi dan hasil kajiannya berlainan. Imunofenotip aberan ini biasanya 
digunakan sebagai penanda untuk penilaian sisa minima penyakit selepas perawatan 
kemoterapi. Pelbagai modaliti telah diwujudkan untuk menilai sisa penyakit 
leukemia akut. Salah satu modaliti yang sesuai dan sensitif yang boleh digunakan 
adalah flositometri. Tujuan kajian ini adalah untuk mengenal pasti kekerapan 
imunofenotip aberan dalam pesakit leukemia akut untuk setempat dan melihat 
perkaitannya dengan data sosiodemografik parameter hematologi, dan kesan rawatan 
selepas kemoterapi fasa induksi. 
 
Kajian retrospektif  telah dijalankan dengan mengumpul 134 sampel pesakit 
leukemia akut yang didiagnos di Hospital USM dalam tempoh masa kajian yang 
ditetapkan. Sampel-sampel tersebut dianalisa untuk imunofenotip menggunakan 
flositometri 4-warna dan perkaitannya dengan data sosiodemografik, pengiraan sel 
darah, ujian  sumsum tulang sewaktu diagnosis, keputusan sitogenetik dan status 
remisi selepas kemoterapi fasa induksi. 
x 
 
Daripada 134 sampel yang dianalisa, seramai 62 pesakit didiagnos sebagai mieloid 
leukemia akut dan B limfoblastik leukemia akut manakala seramai 10 orang pesakit 
didiagnos sebagai T limfoblastik leukemia akut. Dalam AML, CD56 merupakan 
imunofenotip aberan yang paling kerap ditemui diikuti dengan CD7, CD2, CD19 dan 
cyCD79a. Manakala CD13 merupakan imunofenotip aberan paling kerap dijumpai 
dalam BALL diikuti dengan CD56, CD2, CD117, CD16, CD11b, and CD4.Bagi 
TALL pula, kedua-dua CD13 dan CD117 merupakan imunofenotip aberan yang 
paling kerap diikuti dengan CD33, CD71, CD64, CD11b dan cyCD79a. Daripada  
kajian ini juga, didapati CD33 mempunyai perkaitan yang signifkan dengan jantina 
pesakit dalam BALL. Manakala  dalam AML, CD2 mempunyai perkaitan signifikan 
dengan kumpulan umur dan CD7 mempunyai perkaitan signifikan dengan jantina 
pesakit dan bilangan platelet semasa diagnosis. 
 
Daripada kajian ini terdapat bilangan pesakit yang signifikan yang  menunjukkan 
kehadiran imunofenotip aberan sewaktu diagnosis Ini amat berguna untuk 
menghasilkan panel imunofenotip sendiri bagi tujuan pemantauan sisa penyakit 
selepas penerimaan kemoterapi. Selain itu, terdapat penanda-penanda yang tertentu 
menunjukkan perkaitan yang signifikan dengan beberapa parameter hematologi.  
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DETECTION OF LEUKAEMIA- ASSOCIATED ABERRANT 
IMMUNOPHENOTYPE (LAIPs) IN ACUTE LEUKAEMIA AND ITS 
ASSOCIATION WITH HAEMATOLOGICAL PARAMETERS AND 
TREAMENT OUTCOME 
ABSTRACT 
Acute leukaemia is one of the commonest haematological malignancies worldwide. 
Presence of specific and different antigen expressions of leukaemic cells at initial 
presentation help in establishing the diagnosis and specify the lineage involved. 
These leukaemic cells may express leukaemia-associated aberrant immunophenotype 
(LAIPs) at diagnosis. Studies have been done to look for association of these LAIPs 
with known haematological parameters and the results are various. These LAIPs also 
has been used as a marker for assessment of residual disease following respective 
chemotherapy. Many modalities have been developed for its assessment. One of the 
sensitive and convenient methods is multicolour flow cytometry. The aim of this 
study was to identify the frequency of LAIPs in acute leukaemia patient in local as 
well as to look for the association of these markers with sociodemographic data, 
haematological parameters and remission status (post induction chemotherapy).  
 
A retrospective cohort study was done by collecting 134 samples of acute leukaemia 
patient diagnosed in HUSM during the study period. The samples were analysed for 
immunophenotyping using 4-colour flow cytometry and correlate with patients’ 
sociodemographic data, complete blood count, bone marrow aspirate, cytogenetic 
findings as well as morphologic remission status post induction chemotherapy. 
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From 134 samples analysed, both acute myeloid leukaemia (AML) and B acute 
lymphoblastic leukaemia (BALL) were diagnosed in 62 patients each and T acute 
lymphoblastic leukaemia (TALL) seen in 10 cases. In AML, CD56 is the most 
common LAIPs marker found followed by CD7, CD2, CD19 and cyCD79a. 
Whereas, CD 13 is the most common LAIPs found among BALL cases followed by 
CD56, CD2, CD117, CD16, CD11b and CD4. In TALL, both CD13 and CD117 is 
the most common LAIPs marker found followed by CD33, CD71,CD64, CD11b and 
cyCD79a. From this study also, showed CD33 had significant association with 
gender in BALL. Other than that in AML, CD2 had significant association with age 
group and CD7 had significant association with gender and platelet count. 
 
From this study, significant number of acute leukaemia patient in local demonstrate 
presence of LAiPs at diagnosis and this is useful for establishing our own 
immunophenotyping panels for monitoring residual disease following chemotherapy. 
Certain markers had significant association with haematological parameters 
analysed.  
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CHAPTER 1  
INTRODUCTION 
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Acute leukaemia is a type of malignant clonal disorder of immature cells in 
haemopoietic system. It is a consequence of both proliferative lesion and a failure of 
differentiation. This will produce leukaemic cells which have abnormal function and 
failure to progress through normal expected differentiation. This population of cells 
will dominate the bone marrow activity and consequently causing bone marrow 
failure.  
 
Identifying the type of acute leukaemia either acute lymphoblastic leukaemia (ALL) 
or acute myeloid leukaemia (AML) primarily are based on morphological assessment 
as well as detecting patterns of surface antigen expression of leukemic cells by 
immunophenotyping. Each lineage expressed specific patterns of surface antigen and 
according to its maturation stages. 
 
 Leukaemic cells may demonstrate the leukaemia- associated immunophenotype 
(LAIPs) which can be detected at diagnosis. It either defined as antigen 
overexpression, lack of antigen expression asynchronous antigen or cross lineage 
antigen expression (aberrant). In this study we are focusing more on aberrant 
expression of immunophenotype in leukaemia. These LAIPs have potential to be 
used as markers for detection of residual disease. By monitoring the residual disease 
throughout the course of treatment of acute leukaemia, we can deliver the optimal 
treatment based on its progression.  
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Besides, with current World Health Organization’s Classification of Tumours of 
Haemopoietic and Lymphoid Tissues 2008 in which incorporates the molecular, 
genetic and clinical aspect of the haematological malignancies facilitate the 
management of the patients. Based on this classification and a number of parameter 
including age, gender and presenting white blood cell count, current approach for 
acute leukaemia patient which is acute lymphoblastic leukaemia and acute myeloid 
leukaemia are basically based on risk adapted intensification 
 
Meanwhile, certain studies showed these LAIPs have association with short survival 
and increase risk of relapse. It is also associated with lower probabilities to achieve 
complete remission. However, there are studies shows that these LAIPs have no 
significant association with prognosis. 
 
The purpose of this study was to determine the presence of LAIPs in acute leukaemia 
in local by using flow cytometry method at diagnosis. Besides,this study also was to 
look for association of these LAIPs with sociodemographic data, haematological 
parameters and treatment outcome (post induction therapy). These data are beneficial 
in future as it help us to establish the pattern of surface antigen panel to be used in 
flow cytometry to monitor the leukaemic burden in acute leukaemia patient receiving 
chemotherapy.  Therefore, can deliver effective and adequate chemotherapy agent 
based on the individual requirement and response to initial treatment. 
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CHAPTER 2 
LITERATURE 
REVIEW 
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2.1 Introduction of Acute Leukaemia 
2.1.1 Epidemiology of Acute Leukaemia 
Leukaemia is a disease results from the neoplastic proliferation of haemopoietic or 
lymphoid cells. It results from mutation of a single stem cell. Usually it involves 
multiple genetic alterations rather than single event. About 250 000 (2.5%) people 
are diagnosed with leukaemia yearly worldwide. In Europe, 75 700 of new patients 
were diagnosed as leukaemia in 2005(Rodriguez-Abreu et al., 2007b). Meanwhile, 
leukaemia is the commonest childhood cancer in Malaysia. The prevalence was 
about 35 per million .It was the fourth leading cause of death among cancer patient in 
Malaysia in 1998, about  311(6.9%) out of 4498 (Lim, 2002). 
 
Geography and ethnic also show variation in leukaemia. The incidence of leukaemia 
in United States is higher among Caucasians rather than Afro-american and 
Hispanics (Rodriguez-Abreu et al., 2007b). However, study done by (Shirley et al., 
2013) regarding the incidence of acute myeloid leukaemia in ethnic group in England 
shows no significant between the Whites and other ethnic group. There is also no 
evidence of intra-ethnic heterogeneity found in this study. 
 
Acute myeloid leukaemia (AML) is a common leukaemia seen in adult population. 
Small proportion can be seen among early childhood group. It has slightly male 
predominance in adult acute myeloid leukaemia. The incidence is about 1 to 10 per 
100 000 /year between the age of 20 years to 70 years. In acute myeloid leukaemia, 
the median age at presentation  is 70 years old and men is affected more than women, 
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3:2 (Estey and Döhner, 2006). The United State incidence‘s rate among age in year 
2000 to 2003 also quite similar. People age less than 65 years old is 1.8 per 100 000 
persons, whereas those age more than 65 years old is 17 per 100 000 persons. In 
group of patient less than 15 years old, AML comprises 15 to 20% only (Deschler 
and Lubbert, 2006).  
 
Meanwhile, acute lymphoblastic leukaemia (ALL) further subdivided according to 
lineage. About three quarter of cases of ALL is of B- acute lymphoblastic leukaemia 
(B-ALL). And the rest one quarter are of T-acute lymphoblastic leukaemia (T-ALL).  
In contrast to acute myeloid leukaemia, ALL is most commonly seen among age 
group less than 20 years old. The incidence rate among 1 to 4 years old group is 
more than 10 times greater than in the age of 20 to 24 years old. ALL also is slightly 
more in men than women (Rodriguez-Abreu et al., 2007b). B-ALL is commonly 
seen among young age group but the disease occurs at all age. T ALL is more 
commonly seen in male, which is about three quarter of cases. It is common among 
20 to 29 year and 30 to 39 year age group (Marks et al., 2009) 
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2.1.2 Classification, Clinical Features and Risk Factor 
2.1.2 (a)  Classification 
In most cases, acute leukaemia can be classified according to lineage, myeloid or 
lymphoid origin. Acute myeloid leukaemia has been initially categorised based on 
French-American-British (FAB) Classification which is based on cytomorphology 
and cytochemistry. However, based on current WHO classification, it incorporates 
cytogenetic data and defines 4 major categories of AML include acute myeloid 
leukaemia with recurrent genetic abnormalities, acute myeloid leukaemia with 
myelodysplasia-related changes, therapy-related myeloid neoplasms and acute 
myeloid leukaemia, no otherwise specified.(Estey and Döhner, 2006) 
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Table 2.1 :   WHO 2008 Classification of Acute Myeloid Leukaemia 
 
Adapted from (Vardiman et al., 2009) 
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Meanwhile, morphological identification of lymphoblast by microscopy and 
immunophenotypic assessment of lineage by flow cytometry is important for 
diagnosis (Inaba et al., 2013). Acute lymphoblastic leukaemia is usually classified as 
B- acute lymphoblastic leukaemia and T-acute lymphoblastic leukaemia.  
Table 2.2 :   WHO 2008 Classification of Acute Lymphoblastic Leukaemia 
 
Adapted from (Vardiman et al., 2009) 
 
 
2.1.2 (b)  Clinical Features 
The first thing to consider in diagnosing acute leukaemia is the initial clinical 
presentation of the patient. The clinical features of the patient basically results from 
the replacement of the marrow by the leukaemic cells as well as the infiltration of 
them to the other organs such as spleen, liver and lymph nodes. The unregulated 
proliferation the leukaemic cells cause suppression of the normal haemopoietic cells. 
These may result in anaemia, thrombocytopenia or sometimes pancytopenia.  Pallor, 
fatigue, easily bruising,recurrent infection with unexplained cause  and unresolved 
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fever are possible presentations. Organomegaly specifically liver and spleen as well 
as lymphadenopathy are secondary to the infiltration of the leukaemic cells.  
 
Acute myeloid leukaemia shares common clinical features for each subtype. 
However, certain subtype may have particular clinical findings. Hepatosplenomegaly 
is one of the possible clinical findings in acute myeloid leukaemia particularly those 
with predominant monocytic component (Barbara et al., 2010a). Lymphadenopathy 
and infiltration skin, gums and tonsils infiltration are also common in AML with a 
prominent monocytic component. Profound bleeding tendencies and frequently 
followed by disseminated intravascular coagulopathy are usually seen in AML with 
recurrent cytogenetic t(15;17) or known as AML M3 (FAB classification) (Barbara 
et al., 2010a). 
 
On the other hand, common clinical features of B-ALL are including bruises, pallor, 
bone pain, lymphadenopathy and hepatospenomegaly. In majority of B-ALL 
patients, the blasts are present in peripheral blood. As a consequence, the white blood 
cells are increased with normochromic normocytic anaemia and thrombocytopenia 
(Barbara et al., 2010b). However, in T-ALL thymic infiltration is very common and 
maybe associated with pleural and pericardial effusions as well as superior vena cava 
obstruction. Lymphadenopathy and hepatosplenomegaly also can be seen in TALL 
cases.(Barbara et al., 2010b) 
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2.1.2 (c) Risk Factors 
Most of acute myeloid leukaemia arise de novo with no definite exposure to 
leukemogenic factors or agents. Only small number of cases is related to known risk 
factors. These risk factors are include underlying genetic disorder such as Down 
syndrome, chemical or radiation exposure and also chemotherapy (Deschler and 
Lubbert, 2006). Meanwhile, infection is known cause of acute leukaemia in 
childhood acute lymphoblastic leukaemia. Besides, ionising radiation and x-ray 
pelvimetry during pregnancy also have been postulated as part of the contributing 
factor in number of  cases but some believed that it might be not relevant anymore 
(Inaba et al., 2013). 
 
2.1.3   Diagnosis of Acute Leukaemia 
2.1.3 (a)  Complete Blood Count. 
Diagnosis of acute leukaemia is basically started from clinical suspicion when the 
patients came with clinical features suggestive of acute leukaemia. Based on this 
suspicion, then complete blood count is analysed. Both AML and ALL may present 
with leucocytosis, normochromic normocytic anaemia, thrombocytopenia as well as 
numbers of circulating blast cells. But some AML cases may present with low or 
normal white cell count especially in classical AML with t (15; 17) (Barbara et al., 
2010a). Whereas, in T-ALL the white cell count is usually  high but the marrow 
function is better preserved as compared to B-ALL (J.Bain, 2010). 
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2.1.3(b)  Morphology  
Blood and marrow smears are examined by using May-Grunwald-Giemsa or Wright 
Giemsa stain. At least 200 leucocytes on blood smears and 500 nucleated cells on 
marrow smears should be counted. To diagnose acute leukaemia, about 20% of blast 
or more is required either in blood or marrow smears. Except  in certain case of acute 
myeloid leukaemia include t(15;17), t(8;21), inv (16) or t(16;16) and some case of 
erythroleukaemia (Döhner et al., 2010) . On the other hand in acute lymphoblastic 
leukaemia, there are no definite morphological criteria to differentiate between B and 
T lineage. And it’s quite challenging to appreciate B acute lymphoblastic leukaemia 
with normal B lineage precursors known as hematogones (Chiaretti et al., 2014). 
Other than morphologic assessment, cytochemical stain is one of the supplementary 
tests to identify the lineage of acute leukaemia. Presence of at least 3% blast with 
positive for myeloperoxidase (MPO) stain or Sudan black B (SBB) defines that the 
blasts belong to AML. But there are subtypes of AML which are negative for MPO 
stain include monoblast type (J.Bain, 2010). While, acid phosphatase reaction and 
periodic-acid Schiff (PAS) stain helps in identifying the ALL (J.Bain, 2010). 
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Table 2.3 :  Morphologic characteristic of blast cells in acute lymphoblastic 
leukaemia versus acute myeloid leukaemia 
 
Adapted from (Chiaretti et al., 2014) 
 
2.1.3 (c)  Immunophenotyping 
By using multiparametric  flowcytometry at least 3 to 4 colour, we can determine the 
lineage for newly diagnosed acute leukaemia. There are panel of markers available to 
identify each lineage consist of combination of various surface,cytoplasmic as well 
as nuclear antigen markers. No general consensus is provided in determining the cut-
off point to be positive for a marker. Most markers take 20% or more leukaemiac 
cells. Some selected markers take a lower cut off point, 10%. These markers include 
cytoplasmic CD3, MPO,TdT,CD34 and CD117 (Döhner et al., 2010). 
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Table 2.4 : Expression of cell surface and cytoplasmic markers for diagnosis of 
acute myeloid leukaemia and mixed phenotype acute leukaemia 
 
* Adapted from (Döhner et al., 2010) 
 
2.1.3 (d)   Cytogenetic 
Conventional cytogenetic is part of the diagnostic assessment of acute leukaemia.  A 
minimum of 20 metaphase cells analysed from bone marrow is mandatory to 
determine normal karyotype and recommended to define for abnormal karyotype 
(Döhner et al., 2010). It is carried out by microscopic analysis of the chromosomes 
of cells arrested in metaphase. All of the population of leukaemic cells may show the 
same chromosomal abnormality. Sometimes it has more than one additional 
abnormality due to further clonal evolution of the cells (J.Bain, 2010). About 70 to 
80% of AML cases have clonal cytogenetic abnormalities. The commonest 
cytogenetic abnormalities is trisomy 8 followed by anomalies of chromosome 7. 
Some anomalies are found in all morphological subtypes and in both secondary and 
de novo leukaemia such as trisomy 8 and 21. Both of these anomalies are not related 
to morphology and clinical features. On the other hand, t(15;17), t(8;21) and 
15 
 
translocation or inv (16) have a strong association with particular morphology 
subtype (J.Bain, 2010). 
2.1.4  Treatment of Acute Leukaemia 
2.1.4 (a)  Treatment of Acute Lymphoblastic Leukaemia 
Particularly in adult ALL before giving specific regime for chemotherapy usually 
corticosteroid is administered as prephase therapy for tumour reduction. Usually drug 
of choice is prednisolone 20 to 60mg/day or dexamethasone 6 to 16mg/day with or 
without vincristine, cyclophosphamide as well as allopurinol. In certain cases which 
very high white cell count requires leucopheresis (Hoelzer et al., 2016). Supportive 
therapy is required in treating certain condition includes infection and febrile 
neutropenia. Red cell and platelet transfusion and prophylactic granulocyte colony 
stimulating factor (GCSF) is required based on need of the patient. 
 
Basically, treatment regimes include remission induction, consolidation, maintenance 
therapy and also central nervous system (CNS) prophylaxis. In general there are two 
chemotherapy regimes which are commonly followed. First, is the protocol which 
patterned after pediatric BFM (Berlin-Frankfurt-Munster). This protocol mostly used 
in Europian adult ALL. Another approach is by giving alternating intensive 
chemotherapy identical for induction and consolidation such hyperCVAD. This 
protocol is commonly used in United States and other parts of the world (Hoelzer et 
al., 2016). 
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The purpose for remission induction is to achieve complete remission or molecular 
complete remission which is evaluated within 6 to 16 weeks from start of 
chemotherapy. For consolidation usually use systemic high dose therapy includes 
high dose methotrexate, cytarabine ± asparaginase. Meanwhile, for maintenance 
therapy usually use daily mercaptopurine and weekly methotrexate within duration 
2.5 to 3.0 years (Hoelzer et al., 2016).  
 
2.1.4 (b)  Treatment of Acute Myeloid Leukaemia 
Similar with treatment in ALL, in AML as well supportive treatment is also 
important in patient receiving chemotherapy. Leucopharesis is required when there is 
symptomatic hyperleucocytosis but contraindicated in cases suspected acute 
promyelocytic leukaemia as it can exacerbate coagulopathy (British Committee for 
Standards in et al., 2006). Hydration and allopurinol is given to prevent tumor lysis 
syndrome. Red cell transfusion and platelet support as well as antibiotic are given 
based on patient’s need. 
 
Chemotherapy is considered to all patients up to the age of 60 years or in more than 
60 years old but fit to receive treatment. The aim for remission induction is to 
achieve restoration of normal bone marrow function. Complete remission is defined 
as recovery of normal bone marrow cellularity with fewer than 5% blasts and without 
detectable cytogenetic abnormality (British Committee for Standards in et al., 2006). 
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Post remission therapy basically is to prevent relapse with maximal efficiency and 
minimal toxicity. Option of treatment include consolidation chemotherapy and 
autologous,allogeneic related or allogeneic unrelated donor transplantation. 
Maintenance therapy is of benefit in patient with AML who have undergone 
intensive chemotherapy with possible exception of acute promyelocytic leukaemia 
(AML M3 subtype) (British Committee for Standards in et al., 2006). 
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2.2  Prognostic Factors in Acute Leukemia 
2.2.1 Prognostic Factor in Acute Lymphoblastic Leukaemia 
In acute lymphoblastic leukaemia, age (infant or ≥ 10 years old), presenting white 
cell count ≥ 50x 109/L, race (Hispanic or black), male sex and T cell 
immunophenotype are considered as adverse prognostic factors (Inaba et al., 2013). 
Review by (Carroll et al., 2003) noted that both age and white blood cells are 
considered as predictive factors for outcome of the patient in ALL. Based on 
National Cancer Institute/Rome criteria, they stratify as standard risk for those 1 to 
9.99 years old and white blood cell less than or equal to 50 000/µL. Age more than 
or equal to 10 years old and white cell count more than  50 000/µL is considered as 
higher risk (Carroll et al., 2003). There is also a study regarding ALL shows that 
high WBC influence negatively the complete remission duration (Urbano‐Ispizua et 
al., 1990) 
 
Based on the UK National Lymphoblastic Leukaemia (ALL97) childhood acute 
lymphoblastic leukaemia is stratified into 3 risk groups based on the following 
criteria: 
a) Standard Risk :  Age >1<10 years with a highest white cell count before 
treatment of <50x109/L, not have BCR-ABL, no hypodiploidy (<46 
chromosomes) or if 12-24 months old, and no  MLL gene rearrangement. 
b) Intermediate Risk : All children >10 years old, or with a diagnostic  WBC 
>50x109/L (or both), no BCR-ABL, no hypodiploidy (46 chromosomes), or, 
if 12-24 months old, and no  MLL gene rearrangement. 
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c) High Risk : All children, irrespective of initial risk category, who have a slow 
early response (SER) together with those who have BCR-ABL, hypodiploidy 
(46 chromosomes), or, if 12-24 months old, an MLL gene rearrangement. 
 
Table 2.5 :   Unfavorable Prognostic Features in Acute Lymphoblastic 
Leukaemia 
 
Adapted from (Faderl et al., 2010) 
 
There is a study by (Teuffel et al., 2008) showed that ALL with lower haemoglobin 
(less than 8g/dL)  associated with better event free survival as compared to those 
with haemoglobin less than 8 g/dL. This study also showed that significant lower 
haemoglobin in B-ALL with favourable cytgogenetic abnormality which was 
t(12;21) as compared to B-ALL with positive for t(9;22) who had higher 
haemoglobin level. 
 
Regarding cytogenetic status, in  ALL, best prognosis is associated with 
hyperdiploidy which defined as 51 to 65 chromosomes or detected  by demonstrating 
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simultaneous trisomy for chromosomes 4,10 and 17 and with t(12;21)(p13;q22). 
Meanwhile, worst prognosis is associated with t (9;22), MLL gene rearrangement 
and hypodiploidy (J.Bain, 2010). Only small percentages of ALL in childhood are 
positive for Philadelphia whereas in adult ALL up to 40% of cases are positive for 
Philadelphia. This  chromosome abnormality are associated with poor outcome with 
event free survival are 15% or less if treated with chemotherapy alone (Harrison, 
2001). High hyperdiploidy is associated with good prognosis in adult ALL as 
compared in children ALL, 59% had 3-year event free survival (Harrison, 2001). 
 
2.2.2  Prognostic Factors in Acute Myeloid Leukaemia 
In acute myeloid leukaemia,ECOG performance status and high age are associated 
with early death rate. Even when adjusting the performance status, high age is still 
associated with an increased early death rate (p <0.001) (Juliusson et al., 2009). 
Besides, in acute myeloid leukaemia the percentage of favourable cytogenetic in age 
more than 75 years old is 4%, lower than patient in age younger than 56 years old, 
17%. Whereas, the unfavourable cytogenetic in patient younger than 56 years old is 
35%. As compared to those in age more than 75 years old, the percentage is higher, 
51% (Appelbaum et al., 2006) . On the other hand, in a study of AML related to 
treatment outcome, they found that age and total white cell count were not 
significantly associated with treatment outcome (Al-Mawali et al., 2009b). 
 
Besides, acute myeloid leukaemia also can have abnormal cytogenetic finding at 
diagnosis which was about 60% (Grimwade and Hills, 2009). In AML with children 
and adults below age of 55 years, a favourable prognosis is associated with tt(8;21), t 
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(15;17) and inversion 16. Adverse prognosis is associated with -5,-7, del 5q 
abnormalities and complex karyotype (J.Bain, 2010). Those patients whom included 
in favourable cytogenetic risk group, the relapse rate are low if receiving intensive 
chemotherapy. Meanwhile, in adult AML patient with 3q, deletion of 5q, 
monosomies of chromosome 5 and 7 or complex karyotype have very poor 
prognosis. They are candidates for allogenic transplantation (Grimwade and Hills, 
2009) .  
 
2.3  Immunophenotyping in Acute Leukaemia 
2.3.1 Flowcytometry 
Flowcytometry measures the optical and fluorescence characteristic of single cell. 
Size and internal complexity can be determined by forward angle light scatter and 
right-angle scatter respectively. By using multiple fluorochrome, we can assess 
several cell properties simultaneously (Brown and Wittwer, 2000).  In general, fluid 
based specimens include peripheral blood and bone marrow aspirates are suitable for 
best result in flowcytometric evaluation. About 500 000 to 1 million cells are stained 
per tube in order to get the best results. Although as little as 50 000 cells may useful 
enough if the blast population is the predominant component in the specimen (Peters 
and Ansari, 2011). 
 
This method is an ideal tool to study the leucocytes, red cells and platelets. There are 
numbers of clinically relevant aspect of pathophysiology and function that can be 
measured (Orfao et al., 1995). Blast population in acute leukaemia can better isolated 
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by using CD45/side scatter gating for more definitive phenotyping (Brown and 
Wittwer, 2000).  
 
There is numbers of monoclonal antibodies  per analysis tube used, most of the 
clinical laboratories using 3, 4 or 5 colours (using different fluorochromes) (Peters 
and Ansari, 2011).Several monoclonal antibodies for leucocyte differentiation 
antigens will be applied to interested blast/leukaemic cells population in one or 
multicolour staining method.  Pattern of expression of the markers is useful in 
lineage assignment, detect biphenotypic acute leukaemia, to apply current 
immunophenotypic classification and useful for follow up based on abnormal 
expression of markers on leukaemic cells (Béné, 2005).  
 
This immunophenotyping is beneficial in distinguishing myeloid and lymphoid in 
acute leukaemia and minimally differentiated leukaemia (Brown and Wittwer, 2000). 
Panel using as many as 10 colours are coming into clinical use. This advances will 
improve the sensitivity in identifying subtle aberrant immunophenotype, low 
numbers of blast cells in minimal residual diseases and in studies of low cellularity 
sample in which only one or a few tubes only available for analyse (Peters and 
Ansari, 2011). 
 
Other than that, detection of certain markers by immunophenotyping particularly in 
paediatric ALL also can predict the treatment response in future. Children B-ALL 
with positivity of surface immunoglobulin (Sig) has a very poor prognosis if using 
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conventional chemotherapy. However, if the cytoplasmic immunoglobulin also 
present, the prognosis is better even using conventional chemotherapy(Orfao et al., 
1995). This review also found that, detection of minimal residual disease in high 
proportion of ALL cases can be applied by using combination of different panels of 
monoclonal antibodies as this method  able to capture as low as one leukaemic cells 
among 100 000 cells (Orfao et al., 1995). A review done by (Kern et al., 2010) also 
showed there was study found that stronger prognostic power of the post induction 
minimal residual disease assessment by using five-colour flow cytometry. They 
found that post induction minimal residual disease level influenced both relapse free 
survival (RFS) and overall survival (OS). 
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Figure 2.1: Sheath and sample flow pathways for the BD FACSCanto cytometer. 
Adapted from (FACSCanto, 2004) 
 
 
Figure 2.2: Hydrodynamic focusing of the sample are through the flow cells.Adapted 
from (FACSCanto, 2004) 
 
